miR302a-3p May Modulate Renal Epithelial-Mesenchymal Transition in Diabetic Kidney Disease by Targeting ZEB1

Wen-Bin Tang1, Linfeng Zheng1, Renheng Yan1

  • 1Department of Nephrology, Xiangya Hospital, Central South University, Changsha, China.

Nephron
|December 12, 2017
PubMed
Abstract

Insights

MicroRNA 302a-3p plays a protective role in diabetic kidney disease (DKD) by targeting ZEB1 and preventing renal epithelial-mesenchymal transition (EMT). This suggests miR-302a-3p could be a novel therapeutic target for DKD.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Genetics

Background:

  • Diabetic kidney disease (DKD) involves complex molecular pathways, including microRNA (miRNA) dysregulation.
  • Renal epithelial-mesenchymal transition (EMT) is a key process contributing to kidney fibrosis in DKD.

Purpose of the Study:

  • To investigate the specific role of miR-302a-3p in renal EMT within the context of DKD.
  • To explore the potential of miR-302a-3p as a therapeutic target for DKD.

Main Methods:

  • Microarray analysis identified differentially expressed miRNAs in high glucose-stimulated kidney cells (HK-2).
  • Real-time PCR and Western blot were used to assess miR-302a-3p and EMT marker (E-cadherin, vimentin, ZEB-1) expression.
  • In vitro experiments involved transfecting miR-302a-3p mimics and inhibitors into HK-2 cells.
  • Circulating miR-302a-3p levels were measured in DKD patients and correlated with urinary albumin excretion (UAE) and estimated glomerular filtration rate (eGFR).

Main Results:

  • High glucose significantly altered miRNA expression in HK-2 cells, with miR-302a-3p being upregulated.
  • Overexpression of miR-302a-3p suppressed ZEB-1 and reversed high glucose-induced EMT markers (downregulated E-cadherin, upregulated vimentin).
  • Conversely, inhibiting miR-302a-3p promoted EMT.
  • Circulating miR-302a-3p levels were elevated in early DKD but decreased with increasing albuminuria, showing negative correlation with UAE and positive correlation with eGFR in advanced stages.

Conclusions:

  • miR-302a-3p exhibits a protective effect against renal EMT in DKD, potentially by targeting ZEB-1.
  • miR-302a-3p represents a promising biomarker for DKD progression.
  • Targeting miR-302a-3p may offer a novel therapeutic strategy for mitigating renal fibrosis in DKD.

Related Concept Videos